Janssen Vaccines & Prevention B.V.
🇳🇱Netherlands
- Country
- 🇳🇱Netherlands
- Ownership
- -
- Established
- 2000-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.crucell.com
Safety, Tolerability and Immunogenicity Study of Different Vaccine Schedules With Ad26.Mos.HIV and Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2016-02-18
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Janssen Vaccines & Prevention B.V.
- Target Recruit Count
- 36
- Registration Number
- NCT02685020
Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo
Phase 3
Terminated
- Conditions
- Hemorrhagic Fever, Ebola
- Interventions
- Biological: Ad26.ZEBOVBiological: MVA-BN-Filo
- First Posted Date
- 2016-01-22
- Last Posted Date
- 2024-01-02
- Lead Sponsor
- Janssen Vaccines & Prevention B.V.
- Target Recruit Count
- 677
- Registration Number
- NCT02661464
Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo
Phase 2
Completed
- Conditions
- Hemorrhagic Fever, Ebola
- Interventions
- First Posted Date
- 2015-11-05
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Janssen Vaccines & Prevention B.V.
- Target Recruit Count
- 578
- Registration Number
- NCT02598388
Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults
Phase 2
Completed
- Conditions
- Hemorrhagic Fever, Ebola
- Interventions
- Biological: Ad26.ZEBOVBiological: MVA-BN-FiloBiological: Placebo
- First Posted Date
- 2015-09-30
- Last Posted Date
- 2022-03-07
- Lead Sponsor
- Janssen Vaccines & Prevention B.V.
- Target Recruit Count
- 1075
- Registration Number
- NCT02564523
A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants
Phase 3
Completed
- Conditions
- Healthy
- Interventions
- Biological: Ad26.ZEBOV 2*10^10 (vp)Biological: Ad26.ZEBOV 0.8*10^10 (vp)Biological: Ad26.ZEBOV 5*10^10 viral particles (vp)Biological: PlaceboBiological: MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.]Biological: MVA-BN-Filo 5*10^7 Inf. U.
- First Posted Date
- 2015-09-07
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Vaccines & Prevention B.V.
- Target Recruit Count
- 525
- Registration Number
- NCT02543567
Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo
Phase 3
Completed
- Conditions
- Ebola Virus Disease
- Interventions
- Biological: Ad26.ZEBOVBiological: MenACWYBiological: PlaceboBiological: MVA-BN-Filo
- First Posted Date
- 2015-07-28
- Last Posted Date
- 2022-07-18
- Lead Sponsor
- Janssen Vaccines & Prevention B.V.
- Target Recruit Count
- 1023
- Registration Number
- NCT02509494
A Study to Assess Safety, Tolerability, and Immunogenicity of Three Heterologus 2-dose Regimens of the Candidate Prophylactic Vaccines for Ebola in Healthy Adults
Phase 2
Completed
- Conditions
- Ebola Viral Disease
- Interventions
- Biological: MVA-BN-FiloBiological: Ad26.ZEBOVBiological: Placebo
- First Posted Date
- 2015-04-15
- Last Posted Date
- 2021-02-08
- Lead Sponsor
- Janssen Vaccines & Prevention B.V.
- Target Recruit Count
- 423
- Registration Number
- NCT02416453
A Safety and Immunogenicity Study of Heterologous and Homologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Biological: MVA-BN-FiloBiological: Ad26. ZEBOVOther: Placebo
- First Posted Date
- 2014-12-24
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- Janssen Vaccines & Prevention B.V.
- Target Recruit Count
- 164
- Registration Number
- NCT02325050
Safety, Tolerability, and Immunogenicity Study of Homologous Ad26 Mosaic Vector Vaccine Regimens or Heterologous Ad26 Mosaic and MVA Mosaic Vector Vaccine Regimens With Glycoprotein 140 (gp140) for Human Immunodeficiency Virus (HIV) Prevention
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Biological: Ad26.Mos.HIVBiological: gp140 DP Low-doseBiological: MVA-MosaicBiological: gp140 DP High-doseDrug: Placebo
- First Posted Date
- 2014-12-12
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Janssen Vaccines & Prevention B.V.
- Target Recruit Count
- 393
- Registration Number
- NCT02315703
© Copyright 2025. All Rights Reserved by MedPath